# Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

> **NCT04883242** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Washington** · enrollment: 30 (actual)

## Conditions studied

- Recurrent Multiple Myeloma
- Refractory Multiple Myeloma

## Interventions

- **DRUG:** Carfilzomib
- **DRUG:** Dexamethasone
- **BIOLOGICAL:** Isatuximab
- **DRUG:** Pomalidomide
- **PROCEDURE:** Bone Marrow Biopsy
- **PROCEDURE:** Bone Marrow Aspiration
- **PROCEDURE:** Skeletal Survey X-Ray
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Positron Emission Tomography
- **PROCEDURE:** Magnetic Resonance Imaging

## Key facts

- **NCT ID:** NCT04883242
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-07-29
- **Primary completion:** 2026-12-31
- **Final completion:** 2031-12-31
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2026-03-13

## Collaborators

- Genzyme, a Sanofi Company

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04883242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04883242, "Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT04883242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*